Follow
ChromoGenics AB
Nasdaq First North GM (Sweden)
ChromoGenics AB develops and produces dynamic glass with controllable optical properties in Sweden and internationally. The company offers ConverLight, an electrochromic glass, which provides UV protection for use in single glass pane and insulating glass unit solutions. This glass is suitable for new construction, reconstruction, and renovation and offers ultraviolet protection that reduces the risk of fading interiors.
Sector:
INDUSTRIALS
>
Building Products & Equipment
Rights issue
Price
9.50 SEK
Subscription period
25 Nov - 07 Dec 2020
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Show archived
Type
Ticker
ISIN
Market
SHARE
CHRO
SE0014730719
Nasdaq First North GM
Sweden (SE)
Details of share in ChromoGenics AB with ticker CHRO
Status
Active
Order book id
Amount of instruments
7 073 343
Par value
Market cap
Currency
SEK
Segment
First North
First trading date
23 Mar 2017
Terms
Type
Price
Pre-money valuation
Time
Files
IPO
8.50 SEK
80.02M SEK
09 Feb - 24 Feb 2017
IPO in ChromoGenics AB
Type
Price
Pre-money valuation
Time
Files
Rights issue
1.75 SEK
40.63M SEK
08 Jan - 22 Jan 2018
Share issue in ChromoGenics AB
Type
Price
Pre-money valuation
Time
Files
Exercise
10.20 SEK
01 May - 31 May 2018
Option exercise terms for CHRO TO1
Type
Price
Pre-money valuation
Time
Files
Rights issue
0.60 SEK
25.92M SEK
28 Jan - 15 Feb 2019
Share issue in ChromoGenics AB
Type
Price
Pre-money valuation
Time
Files
Rights issue
0.50 SEK
86.38M SEK
25 Jun - 15 Jul 2019
Share issue in ChromoGenics AB
Type
Price
Pre-money valuation
Time
Files
Private placement
0.53 SEK
183.12M SEK
08 Jul 2019
Share issue in ChromoGenics AB
Type
Price
Pre-money valuation
Time
Files
Set-off issue
0.50 SEK
182.19M SEK
21 Aug 2019
Share issue in ChromoGenics AB
Type
Price
Pre-money valuation
Time
Files
Set-off issue
0.56 SEK
210.2M SEK
11 Sep 2019
Share issue in ChromoGenics AB
Type
Price
Pre-money valuation
Time
Files
Exercise
1.74 SEK
10 Jan - 31 Jan 2020
Option exercise terms for CHRO TO2
Type
Price
Pre-money valuation
Time
Files
Rights issue
0.25 SEK
100.6M SEK
19 Feb - 04 Mar 2020
Share issue in ChromoGenics AB
Type
Price
Pre-money valuation
Time
Files
Rights issue
9.50 SEK
67.2M SEK
25 Nov - 07 Dec 2020
Share issue in ChromoGenics AB
Type
Ticker
ISIN
Market
OPTION
2020/2022:1
SE0015195367
Nasdaq First North GM
Sweden (SE)
Details of option in ChromoGenics AB with ticker 2020/2022:1
Status
Inactive
Order book id
Amount of instruments
Market cap
Currency
SEK
First trading date
Terms
One (1) warrant entitles the holder to subscribe for one (1) new share in the Company for the price corresponding to eighty (80) percent of the volume-weighted average price paid for the Company's share on Nasdaq First North GM Sweden during the periods from August 26, 2021 until September 8, 2021 and from February 28, 2022 until March 11, 2022, however, a minimum of SEK 8.00 and a maximum of SEK 12.00 per share. The subscription of shares with the support of warrants shall take place during the periods from September 13, 2021 until September 27, 2021 and from March 16, 2022 until March 31, 2022.
Type
Price
Pre-money valuation
Time
Files
Exercise
8.00-12.00 SEK
13 Sep - 27 Sep 2021
16 Mar - 31 Mar 2022
Option exercise terms for 2020/2022:1
Type
Ticker
ISIN
Market
SHARE
CHRO
SE0009496268
Nasdaq First North GM
Sweden (SE)
Details of share in ChromoGenics AB with ticker CHRO
Status
Archived
Order book id
Amount of instruments
707 334 300
Par value
0.2000
Market cap
Currency
SEK
Segment
First North
First trading date
23 Mar 2017
Terms
Type
Price
Pre-money valuation
Time
Files
IPO
8.50 SEK
80.02M SEK
09 Feb - 24 Feb 2017
IPO in ChromoGenics AB
Type
Price
Pre-money valuation
Time
Files
Rights issue
1.75 SEK
40.63M SEK
08 Jan - 22 Jan 2018
Share issue in ChromoGenics AB
Type
Price
Pre-money valuation
Time
Files
Rights issue
0.60 SEK
25.92M SEK
28 Jan - 15 Feb 2019
Share issue in ChromoGenics AB
Type
Price
Pre-money valuation
Time
Files
Rights issue
0.50 SEK
86.38M SEK
25 Jun - 15 Jul 2019
Share issue in ChromoGenics AB
Type
Price
Pre-money valuation
Time
Files
Private placement
0.53 SEK
183.12M SEK
08 Jul 2019
Share issue in ChromoGenics AB
Type
Price
Pre-money valuation
Time
Files
Set-off issue
0.50 SEK
182.19M SEK
21 Aug 2019
Share issue in ChromoGenics AB
Type
Price
Pre-money valuation
Time
Files
Set-off issue
0.56 SEK
210.2M SEK
11 Sep 2019
Share issue in ChromoGenics AB
Type
Price
Pre-money valuation
Time
Files
Rights issue
0.25 SEK
100.6M SEK
19 Feb - 04 Mar 2020
Share issue in ChromoGenics AB
Type
Ticker
ISIN
Market
SHARE
CHRO
SE0014730719
Nasdaq First North GM
Sweden (SE)
Details of share in ChromoGenics AB with ticker CHRO
Status
Active
Order book id
Amount of instruments
7 073 343
Par value
Market cap
Currency
SEK
Segment
First North
Terms
Type
Price
Pre-money valuation
Time
Files
Rights issue
9.50 SEK
67.2M SEK
25 Nov - 07 Dec 2020
Share issue in ChromoGenics AB
Type
Ticker
ISIN
Market
OPTION
CHRO TO1
SE0009554470
Nasdaq First North GM
Sweden (SE)
Details of option in ChromoGenics AB with ticker CHRO TO1
Status
Archived
Order book id
Amount of instruments
13 921 312
Market cap
Currency
SEK
Trading period
23 Mar 2017 - 29 May 2018
Terms
Four (4) warrants entitles the holder to subscribe for one (1) new share in the Company.
Type
Price
Pre-money valuation
Time
Files
Exercise
10.20 SEK
01 May - 31 May 2018
Option exercise terms for CHRO TO1
Type
Ticker
ISIN
Market
OPTION
CHRO TO2
SE0010662395
Nasdaq First North GM
Sweden (SE)
Details of option in ChromoGenics AB with ticker CHRO TO2
Status
Archived
Order book id
150385
Amount of instruments
18 974 669
Market cap
Currency
SEK
Segment
First North
Trading period
13 Feb 2018 - 29 Jan 2020
Terms
One (1) warrant of series TO 2 entitles the holder to subscribe for one (1) new share in the Company during the period from January 10, 2020 until January 31, 2020 for 3.50 SEK per share.
Update (27.02.2019): Recalculated terms: One (1) warrant of series TO 2 entitles the holder to subscribe for 1.62 new shares in the Company during the period from January 10, 2020 until January 31, 2020 for 2.17 SEK per share.
Update (23.08.2019): Recalculated terms: One (1) warrant of series TO 2 entitles the holder to subscribe for 2.02 new shares in the Company during the period from January 10, 2020 until January 31, 2020 for 1.74 SEK per share.
Type
Price
Pre-money valuation
Time
Files
Exercise
1.74 SEK
10 Jan - 31 Jan 2020
Option exercise terms for CHRO TO2
Type
Ticker
ISIN
Market
OPTION
2020/2022:1
SE0015195367
Nasdaq First North GM
Sweden (SE)
Details of option in ChromoGenics AB with ticker 2020/2022:1
Status
Inactive
Order book id
Amount of instruments
Market cap
Currency
SEK
First trading date
Terms
One (1) warrant entitles the holder to subscribe for one (1) new share in the Company for the price corresponding to eighty (80) percent of the volume-weighted average price paid for the Company's share on Nasdaq First North GM Sweden during the periods from August 26, 2021 until September 8, 2021 and from February 28, 2022 until March 11, 2022, however, a minimum of SEK 8.00 and a maximum of SEK 12.00 per share. The subscription of shares with the support of warrants shall take place during the periods from September 13, 2021 until September 27, 2021 and from March 16, 2022 until March 31, 2022.
Type
Price
Pre-money valuation
Time
Files
Exercise
8.00-12.00 SEK
13 Sep - 27 Sep 2021
16 Mar - 31 Mar 2022
Option exercise terms for 2020/2022:1
People
Number of Employees
29 people
Leif Ljungqvist
CEO
Johan Hedin
Chairman of the board
Peter Gustafson
Board member
Claes-Göran Granqvist
Board member
Anders Brännström
Board member
Mari Broman
Board member
Andreas Jaeger
Board member
Company Details
Sector
INDUSTRIALS

Address
Ullforsgatan 15
Zip code
752 28
City/district
Uppsala
Country
Sweden (SE)
Registration number
556630-1809
LEI code
549300ULKN252K60BG25
First trade date
23 Mar 2017
Registration date
05 Aug 2002
Short name
ChromoGenics

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date